welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
A Registered Cohort Study on Duchenne Muscular Dystrophy
study id #: NCT04012671
condition: Duchenne Muscular Dystrophy
Dystrophinopathy is a term of X-linked recessive genetic disease, including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and the X-linked dilated cardiomyopathy. The aim of this study is to determine the clinical spectrum and natural progression of dystrophinopathy in a prospective multicenter natural history study, to assess the clinical, genetic of patients with dystrophinopathy to optimize clinical management.
mechanism of action: No pharmaceutical intervention
last updated: February 25, 2020
start date: July 1, 2019
estimated completion: December 31, 2039
phase of development: N/A
size / enrollment: 2000
- Age at death [ Time Frame: 20 years ]
The time when patient die
• Eligible Sexes: all
• Beyond 2 years old
• Diagnosis with Duchenne Muscular Dystrophy, and female carriers, genotypically confirmed
• Diagnosis should be supported by muscle biopsy, if no genetic confirmation.
• Presence of other clinically significant illness
other Duchenne content
Valeria Ricotti, MD, PhDDr Valeria Ricotti, originally from Ital...
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyThe main purpose of this study is to tes...
Gihan Tennekoon, MBBS, MRCS, LCRPGihan Tennekoon is an attending neurolog...
Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRSObjective: To evaluate the effects of c...
Sarepta shoots higher as sales of $300,000-a-year drug exceed expectationsSarepta announced second-quarter revenue...
Has outcome changed for adults with Duchenne muscular dystrophy?We investigated the cause of death, the ...
Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne M...Catabasis Pharmaceuticals, Inc., a clini...